The graft-versus-leukemia effect

Current Opinion in Hematology

Volumn 3, Issue 6, 1996, Pages 423-429

  Mavroudis, Dimitrios ^a   Barrett, John ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ANTIGEN PRESENTATION; BONE MARROW TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; GRAFT VERSUS HOST REACTION; HUMAN; LEUKEMIA; LYMPHOCYTE TRANSFUSION; NONHUMAN; PRIORITY JOURNAL; RELAPSE; REVIEW; T LYMPHOCYTE;

EID: 0029857108     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199603060-00005     Document Type: Review

References (73)

1. Barnes D, Loutit J: Treatment of murine leukemia with x-rays and homologous bone marrow. Br J Haematol 1957, 3:241-252.
2. Weiden P, Sullivan K, Flournoy N, et al.: Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981, 304:1529-1531.
3. Goldman J, Gale RP, Horowitz M, et al.: Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: Increased risk of relapse associated with T-cell depletion. Ann Intern Med 1988, 108:806-814.
4. Gale RP, Horowitz M, Ash R, et al.: Identical-twin bone marrow transplants for leukemia. Ann Intern Med 1994, 120:646-652.
5. Sullivan K, Storb R, Buckner C, et al.: Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med 1989, 320:828-834.
6. Slavin S, Or R, Naparstek W, et al.: Cellular-mediated immunotherapy of leukemia in conjunction with autologous and allogeneic bone marrow transplantation in experimental animals and man [abstract]. Blood 1988, 72(suppl 1):407a.
7. Kolb H, Mittermuller J, Clemm Ch, et al.: Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990, 76:2462-2465.
8. Papadopoulos E, Ladanyi M, Emanuel D, et al.: Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994, 330:1185-1191.
9. Weiden P, Flournoy N, Thomas E, et al.: Antileukemic effects of graft-versus-host disease in human recipients of allogeneic marrow grafts. N Engl J Med 1979, 300:1068-1073.
10. Horowitz M, Gale RP, Sondel P, et al.: Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990, 75:555-562.
11. Weaver C, Clift R, Deeg H, et al.: Effect of graft-versus-host disease prophylaxis on relapse in patients transplanted for acute myeloid leukemia. Bone Marrow Transplant 1994, 14:885-893.
12. Blaise D, Olive D, Michallet M, et al.: Impairment of leukemia-free survival by addition of interleukin-2-receptor antibody to standard graft-versus-host prophylaxis. Lancet 1995, 345:1144-1147. When the interleukin-2 receptor antibody 33B3.1 was added to standard post-transplantation immunosuppression with cyclosporine and methotrexate, acute GVHD was delayed but not prevented and leukemia-free survival worsened because of an increase in late relapses.
13. Collins R, Rogers Z, Bennett M, et al.: Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression. Bone Marrow Transplant 1992, 10:391-395.
14. Kolb H, Schattenberg A, Goldman J, et al.: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995, 86:2041-2050. A multicenter report on the efficacy of donor lymphocyte transfusions on acute and chronic leukemias in relapse after BMT.
15. van Rhee F, Kolb H: Donor leukocyte transfusions for leukemic relapse. Curr Opin Hematol 1995, 2:423-430.
16. van Rhee F, Lin F, Cullis J, et al.: Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 1994, 83:3377-3383.
17. Pigneux A, Devergie A, Pochitaloff M, et al.: Recombinant alpha-interferon as treatment for chronic myelogenous leukemia in relapse after allogeneic bone marrow transplantation: a report from the Société Française de Greffe de Moelle. Bone Marrow Transplant 1995, 15:819-824.
18. 7/kg achieved a potent GVL effect with a low risk of GVHD.
19. Drobyski W, Keever C, Roth M, et al.: Salvage Immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood 1993, 82:2310-2318.
20. Giralt S, Hester J, Huh Y, et al.: CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 1995, 86:4337-4343. Infusion of CD8-depleted donor lymphocytes resulted in 60% response and 20% incidence of acute GVHD in 10 patients relapsing after transplantation with various stages of CML.
21. Slavin S, Naparstek E, Nagler A, et al.: Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996, 87:2195-2204. In vitro or in vivo activation of donor lymphocytes with interleukin-2 can induce remissions in relapsed leukemias refractory to donor leukocyte transfusions alone.
22. Mehta J, Powles R, Singhal S, et al.: Cytokine-mediated immunotherapy with or without donor leukocytes for poor-risk acute myeloid leukemia relapsing after allogeneic bone marrow transplantation. Bone Marrow Transplant 1995, 16:133-137.
23. Sica S, Di Mario A, Salutari P, et al.: Chemotherapy and recombinant human granulocyte colony-stimulating factor primed donor leukocyte infusion for treatment of relapse after allogeneic bone marrow transplantation. Bone Marrow Transplant 1995, 16:483-485.
24. Collins R, Wolff S, List A, et al.: Prospective multicenter trial of donor buffy coat infusion for relapsed hematologic malignancy post-allogeneic bone marrow transplantation [abstract]. Blood 1994, 84(suppl 1):333a.
25. Tricot G, Vesole D, Jagannath S, et al.: Graft-versus-myeloma effect: proof of principle. Blood 1996, 87:1196-1198. One of the first two reports of a graft-versus-myeloma effect mediated by donor leukocyte transfusions.
26. Verdonck L, Lokhorst H, Dekker A, et al.: Graft-versus-myeloma effect in two cases. Lancet 1996, 347:800-801. One of the first two reports of a graft-versus-myeloma effect mediated by donor leukocyte transfusions.
27. Naparstek E, Or R, Nagler, et al.: T-cell-depleted allogeneic bone marrow transplantation for acute leukemia using campath-1 antibodies and posttransplant administration of donor's peripheral blood lymphocytes for prevention of relapse. Br J Haematol 1995, 89:506-515. A report on using delayed add-backs of donor lymphocytes to confer the GVL effect after transplantation. Administration was associated with clinically significant GVHD and with decreased relapse rate especially in patients with ALL.
28. Barrett AJ: Strategies to enhance the graft-versus-malignancy effect in allogeneic marrow transplants. Ann N Y Acad Sci 1995, 770:203-213. Review of the immune response mechanisms against the leukemia and introduction of new ways to manipulate the GVL effect with emphasis on the delayed addition of donor lymphocytes to prevent leukemia relapse.
29. van der Harst D, Goulmy E, Falkenburg F, et al.: Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T-cell clones. Blood 1994, 83:1060-1066.
30. Falkenburg F, Goselink H, van der Harst D, et al.: Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes. J Exp Med 1991, 174:27-33.
31. + cytotoxic T-lymphocyte clones isolated from a patient with GVHD that recognize the recipient leukemia cells and therefore may contribute to the GVL effect.
32. Jiang YZ, Kanfer E, MacDonald D, et al.: Graft-versus-leukemia following allogeneic bone marrow transplantation: emergence of cytotoxic T lymphocytes reacting to host leukemia cells. Bone Marrow Transplant 1991, 8:253-258.
33. Harris D: In vitro and in vivo assessment of the graft-versus-leukemia activity of cord blood. Bone Marrow Transplant 1995, 15:17-23.
34. Jiang YZ, Cullis J, Kanfer E, et al.: T cell and NK cell mediated graft-versus-leukemia reactivity following donor buffy coat transfusion to treat relapse after marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplant 1993, 11:133-138.
35. Fuchs E, Bedi A, Jones R, et al.: Cytotoxic T cells overcome BCR-ABL mediated resistance to apoptosis. Cancer Res 1995, 55:463-466.
36. Roger R, Issaad C, Pallardy M, et al.: BCR-ABL does not prevent apoptotic death induced by human natural killer or lymphokine activated killer cells. Blood 1996, 87:1113-1122.
37. Hladik F, Kolbe K, Irschick E, et al.: IL-2, IL-3 and INF-gamma differently affect in vivo frequencies of circulating precursors of cytotoxic T lymphocytes. Ann Hematol 1993, 67:67-74.
38. Richard C, Alsar M, Calavia A, et al.: Recombinant human GM-CSF enhances T cell-mediated cytotoxic function after ABMT for hematological malignancies. Bone Marrow Transplant 1993, 11:473-478.
39. + cells reacting against CML cells can inhibit leukemic granulocyte-macrophage colony-forming unit growth either through direct cytotoxicity or with the production of interferon gamma and tumor necrosis factor in the supernatant.
40. Truitt R, Johnson B: Principles of graft-vs-leukemia reactivity. Biol Blood Marrow Transplant 1995, 1:61-68.
41. + T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow. Bone Marrow Transplant 1991, 8:51-58.
42. Korngold R, Sprent J: T-cell subsets and graft-versus-host disease. Transplantation 1987, 44:335-339.
43. + T cells provide GVL reactivity and facilitate engraftment without inducing severe GVHD.
44. Glass B, Uharek L, Zeis M, et al.: Graft-versus-leukemia activity can be predicted by natural cytotoxicity against leukemia cells. Br J Haematol 1996, 93:412-420.
45. Malkovska V, Cigel F, Armstrong N, et al.: Antilymphoma activity of human gamma/delta T-cells in mice with severe combined immune deficiency. Cancer Res 1992, 52:5610-5614.
46. Kagi D, Vignaux F, Ledermann B, et al.: Fas and perform pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994, 265:528-530.
47. Berke G: The CTL's kiss of death. Cell 1995, 81:9-12.
48. Munker R, Lubbert M, Yonehara S, et al.: Expression of the Fas antigen on primary human leukemia cells. Ann Hematol 1995, 70:15-17.
49. de Bueger M, Bakker A, van Rood J, et al.: Tissue distribution of human minor histocompatibility antigens. J Immunol 1992, 149:1788-1794.
50. den Haan J, Sherman N, Blokland E, et al.: Identification of a graft-versus-host disease associated human minor histocompatibility antigen. Science 1995, 268:1476-1480.
51. Wang W, Meadows L, den Haan J, et al.: Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein. Science 1995, 269:1588-1590. Identification of an 11-residue peptide derived from the SMCY protein and presented by HLA-B7. This male-restricted minor histocompatibility antigen is encoded on the Y chromosome.
52. Goulmy E, Schipper R, Pool J, et al.: Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after allogeneic bone marrow transplantation. N Engl J Med 1996, 334:281-285. The first correlation between mismatch for the HA-1 minor histocompatibility antigen and development of clinically significant GVHD.
53. Hessner M, Endean D, Casper J, et al.: Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia. Blood 1995, 86:3987-3996.
54. Hoffmann T, Theobald M, Bunjes D, et al.: Frequency of bone marrow T cells responding to HLA-identical nonleukemic and leukemic stimulator cells. Bone Marrow Transplant 1993, 12:1-8.
55. van Lochem E, de Gast B, Goulmy E: In vitro separation of host specific graft-versus-host and graft-versus-leukemia cytotoxic T cell activities. Bone Marrow Transplant 1992, 10:181-183.
56. Oettel K, Wesly O, Albertini M, et al.: Allogeneic T-cell clones able to selectively destroy Philadelphia chromosome-bearing (Ph +) human leukemia lines can also recognize Ph- cells from the same patient. Blood 1994, 83:3390-3402.
57. Delain M, Tiberghien P, Racadot E, et al.: Variability of the alloreactive T-cell response to human leukemic blasts. Leukemia 1994, 8:642-647.
58. Matulonis U, Dossiou C, Lament C, et al.: Role of B7-1 in mediating an immune response to myeloid leukemia cells. Blood 1995, 85:2507-2515. Demonstration that the expression of the costimulatory molecule B7-1 was critical for the antigenicity of a murine leukemia.
59. Bunjes D, Theobald M, Hertenstein B, et al.: Successful therapy with donor buffy coat transfusions in patients with relapsed chronic myeloid leukemia after bone marrow transplantation is associated with high frequencies of host-reactive interleukin 2-secreting T helper cells. Bone Marrow Transplant 1995, 15:713-719. Evidence for a role of interleukin-2-secreting T helper cells in the GVL effect of donor lymphocyte infusions.
60. + cells for prevention of graft-versus-host disease after bone marrow transplantation. Transplantation 1994, 57:82-87.
61. Jansen J, Hanks S, Akard L, et al.: Selective T cell depletion with CD8-conjugated magnetic beads in prevention of graft-versus-host disease after allogeneic bone marrow transplantation. Leukemia 1995, 9:271-278.
62. Antin J, Ferrara J: Cytokine dysregulation and acute graft-versus-host disease. Blood 1992, 80:2964-2968.
63. Johnson B, Truitt R: Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance and allows for persistent antileukemic reactivity without severe graft-versus-host disease. Blood 1995, 3302-3312. Murine studies on the effect of timing the delayed add-back of donor lymphocytes to confer the GVL effect without GVHD.
64. Dana A, Barrett J, Jiang YZ, et al.: Distinct T cell populations distinguish chronic myeloid leukemia cells from lymphocytes in the same individual: a model for separating QVHD from GVL reactions. Bone Marrow Transplant 1994, 14:517-524.
65. Mavroudis D, Jiang YZ, Hensel N, et al.: Specific depletion of alloreactivity against haplotype mismatched related individuals by a recombinant immunotoxin: a new approach to graft-versus-host disease prophylaxis in haploidentical bone marrow transplantation. Bone Marrow Transplant 1996, 17:793-799. In haploidentical pairs the reactivity against the unshared haplotype can be specifically depleted without global immunosuppression.
66. Cavazzana-Calvo M, Stephan J, Sarnacki S, et al.: Attenuation of graft-versus-host disease and graft rejection by ex vivo immunotoxin elimination of alloreactive T cells in an H-2 haplotype disparate mouse combination. Blood 1994, 83:288-298.
67. Blazar B, Taylor P, Panoskaltsis-Mortari A, et al.: Coblockade of the LFA1:ICAM and CD28/CTLA4:B7 pathways is a highly effective means of preventing acute lethal graft-versus-host disease induced by fully major histocompatibility complex-disparate donor grafts. Blood 1995, 85:2607-2618. Blocking the costimulatory signals can prevent lethal GVHD in a murine model of major histocompatibility complex-mismatched BMT.
68. Gribben J, Guinan E, Boussiotis V, et al.: Complete blockade of B7 family-mediated costimulation is necessary to induce human alloantigen-specific anergy: a method to ameliorate graft-versus-host disease and extend the donor pool. Stood 1996, 87:4887-4893. Ex vivo induction of host-specific anergy by simultaneous blockade of the B7-1 and B7-2 costimulatory molecules in matched sibling and mismatched pairs.
69. Tiberghien P, Reynolds C, Keller J, et al.: Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T lymphocytes: an approach for specific in vivo donor T-cell depletion after bone marrow transplantation? Blood 1994, 84:1333-1341.
70. Walter E, Greenberg P, Gilbert M, et al.: Reconstitution of cellular Immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995, 333:1038-1044.
71. Rooney C, Smith C, Loftin S, et al.: Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995, 345:9-13. Clinical use of Epstein-Barr virus-specific donor-type T-cell lines to control or prevent Epstein-Barr virus-associated lymphoproliferation after transplantation.
72. Kwak L, Pennington R, Longo D: Active immunization of murine allogeneic bone marrow transplant donors with B-cell tumor-derived idiotype: a strategy for enhancing the specific antitumor effect of marrow grafts. Blood 1996, 87:3053-3060.
73. Kwak L, Taub D, Duffey P, et al.: Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 1995, 345:1016-1020. Prior immunization of the bone marrow donor against tumor-specific antigens may amplify the GVL effect of allogeneic bone marrow grafts.